In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study

ABSTRACT We tested 868 urinary isolates of Escherichia coli collected from 2010 to 2013 as part of the Canadian national surveillance study CANWARD against fosfomycin by using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method with MIC interpretation in accordance with the CLSI M100-S23 (2013) criteria. The concentrations of fosfomycin inhibiting 50 and 90% of the isolates were ≤1 and 4 μg/ml; 99.4% of the isolates were susceptible to fosfomycin.

[1]  P. Ho,et al.  Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. , 2013, Journal of medical microbiology.

[2]  M. Mulvey,et al.  Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. , 2013, The Journal of antimicrobial chemotherapy.

[3]  J. Karlowsky,et al.  Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. , 2013, The Journal of antimicrobial chemotherapy.

[4]  D. van Duin,et al.  Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms , 2012, Antimicrobial Agents and Chemotherapy.

[5]  M. Falagas,et al.  Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. , 2012, The Journal of antimicrobial chemotherapy.

[6]  J. Karlowsky,et al.  In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010 , 2012, Antimicrobial Agents and Chemotherapy.

[7]  R. Raz.  Fosfomycin: an old--new antibiotic. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  Hsiu-Chen Lin,et al.  Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[9]  Patricia J. Simner,et al.  Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study , 2011, Antimicrobial Agents and Chemotherapy.

[10]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Campos,et al.  Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. , 2010, The Journal of antimicrobial chemotherapy.

[12]  M. Hell,et al.  Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli , 2010, Antimicrobial Agents and Chemotherapy.

[13]  Clinical,et al.  Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .

[14]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[15]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[16]  H. Valkenburg.  Epidemiology of urinary tract infections. , 1987, European urology.